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ABSTRACT
Background: Heated tobacco products (HTP) are new forms of tobacco consumption with limited information available on their
use among the general population. Our objective was to analyze the prevalence and associations of use of HTP across 11
countries in Europe.
Methods: Within the TackSHS Project, in 2017–2018 we conducted a cross-sectional study with information on HTP use in the
following countries: Bulgaria, England, France, Germany, Greece, Italy, Latvia, Poland, Portugal, Romania and Spain. In each
country, face-to-face interviews were performed on a representative sample of around 1,000 subjects aged ≥15 years, for a total
of 10,839 subjects.
Results: Overall, 27.8% of study participants were aware of HTPs, 1.8% were ever HTP users (ranging from 0.6% in Spain to
8.3% in Greece), and 0.1% were current users. Men were more frequently HTP ever users than women (adjusted odds ratio
[aOR] 1.47; 95% conﬁdence interval [CI], 1.11–1.95). Ever HTP use was inversely related to age (P for trend <0.001) and more
frequent in ex-smokers (compared with never smokers, aOR 4.32; 95% CI, 2.69–6.95) and current smokers (aOR 8.35; 95% CI,
5.67–12.28), and in electronic cigarette past users (compared with never users, aOR 5.48; 95% CI, 3.46–8.68) and current users
(aOR 5.92; 95% CI, 3.73–9.40).
Conclusions: In 2017–2018, HTP use was still limited in Europe among the general population; however, the dual use of these
products, their high use among younger generations, and the interest of non-smokers in these products are worrying and indicate
the need for close monitoring in terms of prevalence and the characteristics of users.
Key words: heated tobacco products; heat-not-burn tobacco products; IQOS; survey; Europe
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INTRODUCTION
Heated tobacco products (HTP) are electronic devices heating a
tobacco stick to generate an inhalable aerosol containing nicotine
(and other toxicants).1 In December 2014, Phillip Morris
International (PMI) launched in Italy and Japan its ﬁrst HTP,
named IQOS.2–4 This product is now in commerce in most highincome countries, including the majority of European Union (EU)
Member States (MSs). Meanwhile, HTPs from other tobacco
companies (eg, Glo by the British American Tobacco and Ploom
TECH by Japan Tobacco International) are also available in some
EU MSs.
These products raise concerns about their safety.3,5–7 In fact,
although HTPs produce lower levels of some carcinogens and toxic
chemicals compared to conventional cigarettes, they are not riskfree.5,8,9 Moreover, they produce new substances not generated by
conventional cigarettes,7 having uncertain impact on health.10 In
addition, long-term eﬀects of HTPs are still unknown.8
Besides safety problems, HTPs raise serious public health
concerns, similar to those of electronic cigarettes. These include
the dual use with other traditional tobacco products and electronic
cigarettes of the majority of HTP users, the lack of evidence on
the eﬀectiveness of HTPs in assisting smokers to quit, and the
possible “gateway eﬀect” due to the use of these products also by
non-smokers and young adults who are the target of the tobacco
industry and can become addicted to nicotine through HTPs.11–17
Only a few independent studies, mostly from Japan where HTPs
are substantially prevalent4,8,18 and the United States,19 have
investigated the diﬀusion and=or the public health consequences of
HTPs. To our knowledge, data from Europe are limited to three
representative national-based surveys from Italy and United
Kingdom showing a limited but increasing prevalence of
use,2,3,20 and the interest in use by non-smokers3 and adolescents.21
One recent study based on smokers only has identiﬁed factors
related to product use from six European countries.22
The objective of this study was to evaluate HTP spread in
Europe, providing the ﬁrst measure of prevalence and associated
factors related to awareness and use of HTPs in 11 European
countries.

METHODS
Within the Horizon2020 - TackSHS project,23 we conducted a
cross-sectional study, based on a face-to-face survey, in 12
strategically selected European countries: Bulgaria (ﬁeldwork
time: October 2017), England (January–February 2017), France
(November–December 2017), Germany (June 2018), Greece
(June–July 2018), Ireland (November 2017), Italy (November
2016), Latvia (October 2018), Poland (September 2018), Portugal
(November–December 2017), Romania (June–July 2017), and
Spain (October 2017), representing about 80% of the whole
EU population. The detailed methods of the TackSHS survey,
including the questionnaire development, have been explained
elsewhere.23–25 Brieﬂy, in each country we sampled around 1,000
subjects, representative of the general population aged 15 years or
older in terms of age, sex, geographic area, and socioeconomic
characteristics. Subjects were selected mainly through a multistage or a stratiﬁed random sampling. We obtained the approval
of the protocol of the TackSHS survey from a local ethics
committee in each of the 12 countries, and the protocol was
registered inClinicalTrials.gov (ID: NCT02928536).
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After providing their consent to participate, all subjects were
interviewed by ad hoc trained interviewers using computerassisted personal interviewing (CAPI). The survey used a
standardized questionnaire including information on demographic
and socioeconomic characteristics, cigarette smoking and
electronic cigarette use.23,24 The questionnaire was ﬁrst developed
in English and subsequently translated in country-speciﬁc
languages by bilingual (ie, local language and English language)
tobacco control experts. Thus, questions were asked in
participants’ primary languages.
Level of education was categorized as country-speciﬁc tertiles
of schooling years. Self-assessment of household family
economic status relative to the country-speciﬁc population was
classiﬁed into three levels (higher than average, average, and
lower than average). All subjects were asked to answer the
following question: “Have you ever heard about IQOS (the heatnot-burn tobacco cigarette by Philip Morris International); do you
use or did you use it?” (in England, where both IQOS and glo
were in the market: “Have you ever heard about heat-not-burn
tobacco products; do you use or did you use it?”). Possible
answers were: 1) “I have never heard about it”; 2) “I heard about
it but I never used it”; 3) “I have just tried it a couple of times”; 4)
“I used it in the past (not over the last 30 days)”; 5) “I use it
occasionally (5 days or less in the last 30 days)”; 6) “I use it
regularly (more than 5 days in the last 30 days)”. Subjects
answering options 3–6 were classiﬁed as “ever HTP users”, those
answering options 5–6 as “current HTP users”.
eTable 1 shows selected country-speciﬁc information regarding the commercialization of HTPs (eg, month of debut in the
local market). In ﬁve countries the survey was conducted less
than 12 months after HTP introduction (Bulgaria, England,
France, Italy, and Spain) while in six countries it was conducted
at least 12 months after HTP introduction in local markets
(Germany, Greece, Latvia, Poland, Portugal, and Romania).
Moreover, by the time of the survey, no HTP was marketed in
Ireland, thus the question on HTPs was not asked in Ireland.
Excluding Ireland, the survey included a sample of 10,961
subjects from 11 European countries.
Adjusted odds ratios (aORs) and their corresponding 95%
conﬁdence intervals (CIs) for ever HTP use were estimated using
unconditional multiple logistic regression models after adjusting
for sex, age, level of education, and country. To compute
prevalence estimates and aORs we applied a statistical weight to
guarantee the representativeness of the general adult population in
each country; for pooled estimates we further applied a statistical
weight with each country contributing in proportion to its
population aged 15 years or over.26 Statistical analyses were
performed using SAS 9.4 (SAS Institute; Cary, NC, USA).

RESULTS
Of 10,961 subjects from 11 European countries, 10,839 (98.9%)
provided valid responses on HTP awareness and use, and were
included in this analysis. Overall, 72.2% had never heard about
HTPs (from 53.0% in Greece to 84.6% in Spain), 26.0% had heard
about these products but never used them (from 13.4% in
Romania to 38.7% in Greece), 1.5% had tried them once or twice,
0.1% were past users and 0.1% were current users (Table 1).
Overall, 1.8% of respondents described themselves as ever HTP
users (from 0.6% in Spain to 8.3% in Greece). Men were more
frequently HTP ever users than women (aOR 1.47; 95% CI,
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Table 1. Odds ratiosa (OR) for heated tobacco product (HTP) ever vs never use and corresponding 95% conﬁdence intervals (CI) in the
European population aged ;15 years, according to selected individual-level characteristics. TackSHS, 2017–2018

Totalb
N

TOTAL
Country (month of ﬁeldwork)
Bulgaria (Oct 2017)
England (Jan–Feb 2017)
France (Nov–Dec 2017)
Germany (Jun 2018)
Greece (Jun–Jul 2018)
Italy (Nov 2016)d
Latvia (Oct 2018)
Poland (Sep 2018)
Portugal (Nov–Dec 2017)
Romania (Jun–Jul 2017)
Spain (Oct 2017)
Sex
Women
Men
Age, yearse
15–25
25–44
45–64
≥65
P for trend
Educationf
Low
Medium
High
P for trend
Household economic statusf
Lower than average
Average
Higher than average
P for trend
Smoking status
Never smokers
Ex-smokers
Current smokers
Electronic cigarette statusf
Never users
Past users
Current users

Subjects
unaware of
HTP
%

Subjects aware of HTP, %
HTP ever users
Never tried

Just triedc

Past users

Current users

All ever users
N b (%)

OR (95% CI)

10,839

72.2

26.0

1.5

0.1

0.1

268 (1.8)

1,050
1,013
1,018
1,012
1,000
1,059
936
724
1,000
1,001
1,026

78.7
69.1
79.1
64.2
53.0
74.7
66.4
63.7
64.5
83.6
84.6

19.3
28.8
19.2
34.3
38.7
24.2
31.8
34.7
32.5
13.4
14.7

1.5
1.5
1.4
1.3
6.8
1.1
1.8
1.6
2.5
2.6
0.6

0.2
0.4
0.2
0.0
0.5
0.0
0.1
0.1
0.0
0.4
0.0

0.3
0.2
0.2
0.1
1.0
0.0
0.0
0.0
0.5
0.0
0.1

21
21
18
16
83
10
17
11
30
30
11

5,727
5,112

76.5
67.5

22.1
30.4

1.2
1.9

0.1
0.2

0.2
0.1

109 (1.4)
159 (2.1)

1
1.47 (1.11–1.95)

1,350
3,699
3,922
1,838

69.0
65.9
71.7
86.8

28.3
31.8
26.7
12.9

2.3
1.9
1.5
0.2

0.4
0.1
0.1
0.0

0.0
0.2
0.1
0.1

42 (2.7)
154 (2.3)
66 (1.7)
6 (0.3)

1
0.84 (0.57–1.22)
0.63 (0.43–0.94)
0.14 (0.06–0.32)
<0.001

4,136
3,799
2,901

76.8
70.4
67.8

21.7
27.8
30.0

1.3
1.6
1.7

0.1
0.1
0.3

0.1
0.2
0.2

68 (1.5)
107 (1.8)
93 (2.2)

1
0.99 (0.70–1.40)
1.30 (0.91–1.86)
0.166

2,711
5,624
1,394

78.1
74.4
68.3

20.4
23.9
29.0

1.1
1.5
2.3

0.3
0.1
0.2

0.1
0.1
0.3

49 (1.5)
150 (1.7)
51 (2.8)

1
0.99 (0.66–1.48)
1.61 (0.99–2.63)
0.060

5,828
1,886
3,125

76.7
70.8
63.2

22.8
27.2
32.5

0.4
1.8
3.7

0.0
0.1
0.5

0.1
0.1
0.3

26 (0.5)
41 (2.0)
201 (4.4)

1
4.32 (2.69–6.95)
8.35 (5.67–12.28)

10,295
291
247

73.1
54.9
56.1

25.5
36.2
34.9

1.2
7.1
6.5

0.1
0.8
0.9

0.1
1.0
1.6

194 (1.4)
42 (8.9)
32 (8.9)

1
5.48 (3.46–8.68)
5.92 (3.73–9.40)

(2.0)
(2.1)
(1.8)
(1.4)
(8.3)
(1.1)
(1.8)
(1.6)
(3.0)
(3.0)
(0.6)

1.68
1.63
1.46
1.28
6.61
1
1.47
1.36
2.57
2.61
0.53

(0.58–4.88)
(0.92–2.86)
(0.83–2.55)
(0.73–2.23)
(3.63–12.04)
(0.19–11.53)
(0.71–2.58)
(1.16–5.70)
(1.35–5.02)
(0.24–1.18)

CI, conﬁdence interval; HTP, heated tobacco products; OR, odds ratio.
a
ORs and their corresponding 95% CIs were estimated using unconditional multiple logistic regression models adjusting for sex, age, level of education, and
country. Estimates in bold are statistically signiﬁcant at 0.05 level.
b
Unweighted number of subjects with available information on HTP use (N = 10,839) or unweighted number of ever users of HTPs (N = 268).
c
Subjects reporting to have tried HTP a couple of times.
d
Italy was used as the pilot country, thus, its ﬁeldwork was anticipated to November 2016. Italy has been chosen as the reference category because it is the ﬁrst
European country where IQOS was launched.
e
Participants’ age was ≥15 years in all countries, except England (≥16), Ireland (≥18), Greece (15–64), and Latvia (15–74).
f
The sum does not add up to the total because of few missing values. In particular, 3 subjects had missing information on level of education and 6 subjects had
missing information on electronic cigarette use. Moreover, the variable on self-assessment of the household (family) economic status relative to the countryspeciﬁc population was missing in all German participants (n = 1,012) plus further 98 subjects.

1.11–1.95). Ever use was inversely related to age (compared with
<25 years, aOR 0.84; 95% CI, 0.57–1.22 for 25–44 years; aOR
0.63; 95% CI, 0.43–0.94 for 45–64 years; and aOR 0.14; 95% CI,
0.06–0.32 for ≥65 years of age; P for trend <0.001). Ever HTP
use was more frequent in ex-smokers (compared with never
smokers, aOR 4.32; 95% CI, 2.69–6.95) and current smokers
(aOR 8.35; 95% CI, 5.67–12.28), and in electronic cigarette past

users (compared with never users, aOR 5.48; 95% CI, 3.46–8.68)
and current users (aOR 5.92; 95% CI, 3.73–9.40). No statistically
signiﬁcant relationship was observed between HTP use and
socio-economic characteristics, including level of education and
household economic status.
In countries where HTPs were introduced less than 12 months
before the survey conduction, the prevalence of HTP awareness
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was 23.3% and that of HTP ever users was 1.4%. Corresponding
estimates in countries where HTPs were introduced more than 12
months before the survey conduction were 34.3% and 2.2%
(P < 0.001 and P = 0.001 for awareness and use, respectively).
Among 41 HTP ever users and ex-cigarette smokers at the time
of the survey, 20 (49%) quit smoking before HTPs were
introduced in the local market of each country.

DISCUSSION
This study provides the prevalence and factors related to the HTP
use among the general population in multiple European countries.
We found that the prevalence of ever HTP use (and the frequency
of use) was still low. Overall, almost 2% of European adults
already tried (or used) HTPs, with a wide variation between
countries. Young people, men, ever smokers, and electronic
cigarette users were more likely to be attracted to these new
products, in line with previous researches.21,27 The large variation
in HTP awareness (ranging between 15% and 47%) and use
(ranging between 1% and 8%) also reﬂects diﬀerences in the
commercialization of these products. In fact, countries with a
shorter experience of HTPs (ie, with time since HTPs
introduction in the local market lower than 12 months at the
time of the survey) were those with a lower awareness and use of
these tobacco products.
Subjects aged 15–24 years have more frequently tried HTPs, in
agreement with previous ﬁndings.15,20 This suggests that the
youngest generations could be the key target subpopulation of
HTP marketing promotions. However, the number of current
HTP users among the young is null, likely due to the relatively
expensive device—as compared to electronic cigarette—that
discourages initiation for a regular use.17
Although no statistically signiﬁcant relationship has been
observed between the use of HTP and socioeconomic characteristics, wealthier subjects systematically reported the highest levels
of HTP awareness and use, in line with previous studies.3,20
The majority of HTP ever users were dual users (ie also
smokers of conventional cigarettes). This raises concerns that,
similar to what has been observed for electronic cigarettes,28–30
HTPs could also be used in places where combustible cigarettes
are not permitted while HTPs are not covered by the national
legislation. These ﬁndings are in line with a recent research
conducted among 6,027 smokers from 6 EU MSs according to
which ever use of HTPs was signiﬁcantly higher among those who
had tried to quit smoking in the last 12 months, had tried electronic
cigarettes during their lifetime and among those that perceived
HTPs as less dangerous than combustible cigarettes.22 A
qualitative study conducted in the United Kingdom in 2018 found
that IQOS users mostly experimented with IQOS to reduce or
to stop smoking combustible cigarettes due to health risks,
perceiving IQOS as an (healthier) alternative way to continue
smoking.17 Moreover, only a few had completely stopped
smoking both IQOS and combustible cigarettes, as people mainly
used IQOS in place of (or alongside) traditional cigarettes.17
In line with the current evidence,3 our study found that a
limited but not negligible proportion of HTP users (ie, 10% of
all HTP ever users) were never smokers, suggesting that these
products are attracting towards nicotine dependence new
segments of population, with potentially diﬀerent characteristics
from those known to be associated with exclusive tobacco
consumption. Moreover, almost half of ex-smokers who used
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HTPs quit smoking before HTPs were launched in the local
markets. This supports the fact that a large proportion of exsmokers using HTPs are not people switching to HTPs to reduce
their harm, but people who relapse nicotine addiction, being
attracted by this new alleged safe product. How HTPs are
attracting non-smokers to nicotine addiction is a matter of
concern that requires further research.
This study has some weaknesses, mainly related to its crosssectional design. Although the overall sample size is large, our
study is based on a small sample of European HTP users. In many
countries the survey was conducted only a few months after HTP
introduction into the market, and the ﬁeldwork was conducted in
diﬀerent time periods (ranging between November 2016 and
October 2018), making the comparisons of HTP use among
countries diﬃcult. Furthermore, some diﬀerences in terms of
sampling methodology used24 add complexity to the interpretation of the results. Moreover, no pictures of heated tobacco
products were shown to participants during the interviews. This,
together with some possible diﬀerences in the wording of
questions asked in various countries, may have resulted in a
response bias. The strengths of our survey include the
representativeness of the adult population of the included
European countries in terms of age, sex and habitat, and the
use of face-to-face interview. More importantly, this is the ﬁrst
European study evaluating the spread of HTP among the general
population, using the same standardized questionnaire in diﬀerent
countries. Therefore, our estimates may serve as key baseline
measures for future studies.
Our study shows that only 0.1% of Europeans currently use
HTPs. Once generalized to the 28 EU MSs, our estimate is
compatible with more than half million adults currently using
this product. Our data show that HTPs are: i) mainly used in
combination with other products, ii) mainly used by the youngest
generations, and iii) also used by (and likely promoted to) never
smokers. These ﬁndings are worrying and indicate the need
for close monitoring of prevalence, trends and determinants of
HTP use. Our study could be useful to support the planning,
implementation and monitoring of targeted prevention intervention, as well as inform decision making at the normative and
public health level in Europe.

ACKNOWLEDGMENTS
Authors would like to thank Liliane Chatenoud, Tobias Eﬀertz,
Filippos T Filippidis, Gergana Geshanova, Sheila Keogan,
Hristo Ivanov, José Precioso, Krzysztof Przewozniak, Polina
Starchenko, Vergina K Vyzikidou for their help in the preparation, translation and=or submission of the study protocol to local
ethics committees. IDIBELL group thanks CERCA Programme
Generalitat de Catalunya for the institutional support.
Conﬂicts of interest: KP obtained grants and personal fees
from the Polish League Against Cancer (Polska Liga Walki
Z Rakiem) and from Start-up Helping Hand Powered by
addictions.ai, outside the submitted work.
Contributors: SG and EF had the original study idea; EF, GG
and AL contributed to the ﬁnalization of the survey questionnaire;
XL, AL and EB carried out the statistical analysis; SG drafted the
article in collaboration with XL, EB and AL; all other authors
made substantial contributions to conception, design and
interpretation of data; all the authors approved the ﬁnal version
of the manuscript.

Gallus S, et al.

Funding: This project has received funding from the European
Union Horizon 2020 research and innovation programme under
grant agreement No 681040. The Tobacco Control Unit (ICO) is
partially supported by the Ministry of Universities and Research,
Government of Catalonia (2017SGR139). EF was partially
supported by the Instituto de Salud Carlos III, Government of
Spain (INT16=00211 and INT17=00103), co-funded by the
European Regional Development Fund (FEDER). The work of
SG, EB, and AL was partially funded by the Italian League
Against Cancer (LILT, Milan). The sponsors did not participate
in the study design; data collection, analysis, and interpretation;
or the preparation or submission of this report.
Disclaimer: This paper reﬂects only the authors’ views and the
European Commission is not responsible for any use that may be
made of the information it contains.
Data availability statement: Data are available upon reasonable
request. Please see at www.TackSHS.eu the conditions of use and
how to request the data.

APPENDIX A. SUPPLEMENTARY DATA
Supplementary data related to this article can be found at https:==
doi.org=10.2188=jea.JE20200248.
REFERENCES
1. Auer R, Concha-Lozano N, Jacot-Sadowski I, Cornuz J, Berthet A.
Heat-not-burn tobacco cigarettes: smoke by any other name. JAMA
Intern Med. 2017;177:1050–1052.
2. Liu X, Lugo A, Spizzichino L, et al. Heat-not-burn tobacco products
are getting hot in Italy. J Epidemiol. 2018;28:274–275.
3. Liu X, Lugo A, Spizzichino L, et al. Heat-not-burn tobacco products: concerns from the Italian experience. Tob Control. 2019;28:
113–114.
4. Tabuchi T, Gallus S, Shinozaki T, et al. Heat-not-burn tobacco
product use in Japan: its prevalence, predictors and perceived
symptoms from exposure to secondhand heat-not-burn tobacco
aerosol. Tob Control. 2018;27:e25–e33.
5. WHO. Heated tobacco products (HTPs) market monitoring information sheet. Available at: https:==apps.who.int=iris=bitstream=handle=
10665=273459=WHO-NMH-PND-18.7-eng.pdf?ua=1. 2018.
6. Stephens WE. Comparing the cancer potencies of emissions from
vapourised nicotine products including e-cigarettes with those of
tobacco smoke. Tob Control. 2018;27:10–17.
7. St Helen G, Jacob Iii P, Nardone N, Benowitz NL. IQOS:
examination of Philip Morris International’s claim of reduced
exposure. Tob Control. 2018;27(Suppl 1):s30–s6.
8. Jankowski M, Brożek GM, Lawson J, et al. New ideas, old
problems? Heated tobacco products - a systematic review. Int J
Occup Med Environ Health. 2019;32:595–634.
9. Glantz SA. Heated tobacco products: the example of IQOS. Tob
Control. 2018;27(Suppl 1):s1–s6.
10. Chun L, Moazed F, Matthay M, Calfee C, Gotts J. Possible
hepatotoxicity of IQOS. Tob Control. 2018;27(Suppl 1):s39–s40.
11. Liu X, Lugo A, Davoli E, et al. Electronic cigarettes in Italy: a tool
for harm reduction or a gateway to smoking tobacco? Tob Control.
2020;29(2):148–152.
12. World Health Organization. WHO Report on the Global Tobacco
Epidemic, 2019. Oﬀer help to quit tobacco use. Available at: https:==
www.who.int=tobacco=global_report=en=. 2019.
13. World Health Organization. WHO Statement on ENDS=ENNDS.
Available
at:
https:==www.who.int=tobacco=communications=
statements=eletronic-cigarettes-january-2017=en=. 2019.
14. Filippidis FT, Laverty AA, Gerovasili V, Vardavas CI. Two-year
trends and predictors of e-cigarette use in 27 European Union
member states. Tob Control. 2017;26:98–104.

15. Marynak KL, Wang TW, King BA, et al. Awareness and ever use of
“heat-not-burn” tobacco products among U.S. adults, 2017. Am J
Prev Med. 2018;55:551–554.
16. McKelvey K, Popova L, Kim M, et al. Heated tobacco products
likely appeal to adolescents and young adults. Tob Control. 2018;
27(Suppl 1):s41–s47.
17. Tompkins CNE, Burnley A, McNeill A, Hitchman SC. Factors that
inﬂuence smokers’ and ex-smokers’ use of IQOS: a qualitative study of
IQOS users and ex-users in the UK. Tob Control. 2021;30(1):16–23.
18. Tabuchi T, Kiyohara K, Hoshino T, et al. Awareness and use of
electronic cigarettes and heat-not-burn tobacco products in Japan.
Addiction. 2016;111:706–713.
19. Nyman AL, Weaver SR, Popova L, et al. Awareness and use of
heated tobacco products among US adults, 2016–2017. Tob Control.
2018;27(Suppl 1):s55–s61.
20. Brose L, Simonavicius E, Cheeseman H. Awareness and use of
‘heat-not-burn’ tobacco products in Great Britain. Tob Regul Sci.
2018;4:44–50.
21. Czoli CD, White CM, Reid JL, OConnor RJ, Hammond D.
Awareness and interest in IQOS heated tobacco products among
youth in Canada, England and the USA. Tob Control. 2020;29:89–95.
22. Lotrean LM, Trofor A, Radu-Loghin C, et al. Awareness and use of
heated tobacco products among adult smokers in six European
countries: Findings from the EUREST-PLUS ITC Europe Surveys.
Eur J Pub Health. 2020;30(Suppl_3):iii78–iii83.
23. Fernández E, López MJ, Gallus S, et al. Tackling second-hand
exposure to tobacco smoke and aerosols of electronic cigarettes: the
TackSHS project protocol. Gac Sanit. 2020;34:77–82.
24. Gallus S, Lugo A, Liu X, et al. Who smokes in Europe? Data
from 12 European countries in the TackSHS survey (2017–2018).
J Epidemiol. 2021;31(2):145–151.
25. Amalia B, Liu X, Lugo A, et al. Exposure to secondhand aerosol of
electronic cigarettes in indoor settings in 12 European countries: data
from the TackSHS survey. Tob Control. 2021;30(1):49–56.
26. Eurostat. Population on 1 January by age and sex. Available online
at https:==ec.europa.eu=eurostat=data=database. 2017.
27. Hwang JH, Ryu DH, Park SW. Heated tobacco products: cigarette
complements, not substitutes. Drug Alcohol Depend. 2019;204:
107576.
28. Gallus S, Borroni E, Liu X, et al. Electronic cigarette use among
Italian smokers: patterns, settings and adverse events. Tumori. 2020;
106(3):229–240.
29. Goldberg RL, Cataldo JK. Using an e-cigarette is like eating tofu
when you really want meat. Am J Health Behav. 2018;42:54–64.
30. Shi Y, Cummins SE, Zhu SH. Use of electronic cigarettes in smokefree environments. Tob Control. 2017;26:e19–e22.

The TackSHS Project Investigators:
Catalan Institute of Oncology (ICO); Bellvitge Biomedical
Research Institute (IDIBELL), Spain: Esteve Fernández,
Yolanda Castellano, Marcela Fu, Montse Ballbè, Beladenta
Amalia, Olena Tigova
Public Health Agency of Barcelona (ASPB), Spain: Maria José
López, Xavier Continente, Teresa Arechavala, Elisabet Henderson
Istituto di Ricerche Farmacologiche Mario Negri IRCCS
(IRFMN), Italy: Silvano Gallus, Alessandra Lugo, Xiaoqiu Liu,
Elisa Borroni; Istituto DOXA, Worldwide Independent Network=Gallup International Association, Italy: Paolo Colombo
University of Stirling (UNISTIR), the UK: Sean Semple,
Rachel O’Donnell, Ruaraidh Dobson
TobaccoFree Research Institute Ireland (TFRI), Ireland:
Luke Clancy, Sheila Keogan, Hannah Byrne
Hellenic Cancer Society - George D. Behrakis Research Lab
(HCS), Greece: Panagiotis Behrakis, Anna Tzortzi, Constantine
Vardavas, Vergina Konstantina Vyzikidou, Gerasimos Bakelas,
George Mattiampa

J Epidemiol 2022;32(3):139-144

j

143

Heated Tobacco Products in Europe

Fondazione IRCCS Istituto Nazionale dei Tumori (INT),
Italy: Roberto Boﬃ, Ario Ruprecht, Cinzia De Marco, Alessandro
Borgini, Chiara Veronese, Martina Bertoldi, Andrea Tittarelli
Istituto per lo Studio, la Prevenzione, e la Rete Oncologica
(ISPRO), Italy: Giuseppe Gorini, Giulia Carreras, Barbara
Cortini, Simona Verdi, Alessio Lachi, Elisabetta Chellini
Polytechnic University of Cartagena (UPCT), Spain: Ángel

144

j

J Epidemiol 2022;32(3):139-144

López Nicolás, Marta Trapero-Bertran, Daniel Celdrán Guerrero
European Network on Smoking and Tobacco Prevention
(ENSP), Belgium: Cornel Radu-Loghin, Dominick Nguyen,
Polina Starchenko
Hospital Universitario La Princesa (IISP), Spain: Joan B
Soriano, Julio Ancochea, Tamara Alonso, María Teresa Pastor,
Marta Erro, Ana Roca, Patricia Pérez, Elena García Castillo

